» Articles » PMID: 15708927

Psoriatic Arthritis: Epidemiology, Clinical Features, Course, and Outcome

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2005 Feb 15
PMID 15708927
Citations 520
Authors
Affiliations
Soon will be listed here.
Abstract

Psoriatic arthritis (PsA) has been defined as a unique inflammatory arthritis associated with psoriasis. Its exact prevalence is unknown, but estimates vary from 0.3% to 1% of the population. The clinical features described initially are recognised by most experienced clinicians, although they are most distinct in early disease. Initially, PsA typically presents as an oligoarticular and mild disease. However, with time PsA becomes polyarticular, and it is a severe disease in at least 20% of patients. Patients with PsA who present with polyarticular disease are at risk for disease progression. In addition to progression of clinical and radiological damage, health related quality of life is reduced among patients with PsA. It important to note that patients included in recent drug trials resemble patients followed prospectively in a clinic.

Citing Articles

Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis.

Zabotti A, Aydin S, David P, Di Matteo A, McGonagle D Nat Rev Rheumatol. 2025; .

PMID: 40075177 DOI: 10.1038/s41584-025-01229-6.


Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls.

Christensen I, Lillegraven S, Sexton J, Kvien T, Uhlig T, Provan S Rheumatol Adv Pract. 2025; 9(1):rkaf017.

PMID: 40061449 PMC: 11889454. DOI: 10.1093/rap/rkaf017.


An integrated multi-omics analysis identifies protein biomarkers and potential drug targets for psoriatic arthritis.

Cai Y, Zheng D, Chen X, Bai Z, Zhang J, Deng W Commun Biol. 2025; 8(1):240.

PMID: 39953266 PMC: 11828935. DOI: 10.1038/s42003-025-07698-5.


A self-management intervention for newly diagnosed with inflammatory arthritis: a randomized controlled feasibility and fidelity study.

Lindgren L, Thomsen T, Hetland M, Aadahl M, Kristensen S, de Thurah A Pilot Feasibility Stud. 2025; 11(1):15.

PMID: 39934926 PMC: 11817759. DOI: 10.1186/s40814-025-01601-z.


FGF7 as an essential mediator for the onset of ankylosing enthesitis related to psoriatic dermatitis.

Ebihara S, Owada Y, Ono M Life Sci Alliance. 2025; 8(4).

PMID: 39919800 PMC: 11806258. DOI: 10.26508/lsa.202403073.


References
1.
Ory P . Radiography in the assessment of musculoskeletal conditions. Best Pract Res Clin Rheumatol. 2003; 17(3):495-512. DOI: 10.1016/s1521-6942(03)00022-6. View

2.
Helliwell P, Taylor W . Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis. 2005; 64 Suppl 2:ii3-8. PMC: 1766878. DOI: 10.1136/ard.2004.032318. View

3.
Kane D, Stafford L, Bresnihan B, FitzGerald O . A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003; 42(12):1460-8. DOI: 10.1093/rheumatology/keg384. View

4.
Savolainen E, Kaipiainen-Seppanen O, Kroger L, Luosujarvi R . Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey. J Rheumatol. 2003; 30(11):2460-8. View

5.
McKenna S, Doward L, Whalley D, Tennant A, Emery P, Veale D . Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis. 2004; 63(2):162-9. PMC: 1754880. DOI: 10.1136/ard.2003.006296. View